Health Catalyst Stock Intrinsic Value – HEALTH CATALYST Announces Financial Results for Q2 FY 2023
August 12, 2023
🌥️Earnings Overview
On August 8, 2023, HEALTH CATALYST ($NASDAQ:HCAT) revealed its financial results for the second quarter of the fiscal year 2023 (ending June 30, 2023). This quarter saw total revenue increase by 3.7% year-on-year, totaling USD 73.2 million while net income declined by 2.5%, amounting to USD -32.6 million compared to the same period of the previous year (-33.4 million).
Market Price
The stock opened at $13.3 and closed at $13.0, representing a decrease of 4.4% from the previous closing price of 13.5. This decrease reflects the current market sentiment towards the company’s performance, as their financial reports show that net income for the quarter was lower than expected. Overall, the financial results reflect a slight decline in revenue year-over-year. This downturn is mainly attributed to decreased demand for products and services due to the economic impacts of the pandemic.
Despite this decline, HEALTH CATALYST is still well-positioned to take advantage of growth in the healthcare technology sector and is planning to invest more in research and development in order to continue to innovate and stay competitive. Looking ahead, the company’s management is optimistic about the future prospects of HEALTH CATALYST and expects that revenue should increase in the coming quarters. With a strong focus on innovation and customer engagement, HEALTH CATALYST is confident that they will be able to capitalize on their unique strengths in order to maximize shareholder value. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Health Catalyst. More…
| Total Revenues | Net Income | Net Margin |
| 284.6 | -147.32 | -51.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Health Catalyst. More…
| Operations | Investing | Financing |
| -44.01 | -11.69 | -5.61 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Health Catalyst. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 722.9 | 333.04 | 6.93 |
Key Ratios Snapshot
Some of the financial key ratios for Health Catalyst are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 18.4% | – | -51.7% |
| FCF Margin | ROE | ROA |
| -21.3% | -23.1% | -12.7% |
Analysis – Health Catalyst Stock Intrinsic Value
At GoodWhale, we have been analyzing the financials of HEALTH CATALYST in order to determine a fair value of their stock. Our proprietary Valuation Line has come to the conclusion that the fair value of the HEALTH CATALYST share is currently around $31.5. Unfortunately, HEALTH CATALYST’s stock is currently being traded at a lower price point of $13.0, representing an undervaluation of 58.7%. More…
Peers
The company’s products and services enable healthcare organizations to optimize their clinical and financial performance. Health Catalyst‘s competitors include RYAH Group Inc, Sophia Genetics SA, and Convey Health Solutions Holdings Inc. These companies offer data and analytics solutions to healthcare organizations that help them improve their clinical and financial performance.
– RYAH Group Inc ($OTCPK:RYAHF)
Auryah Group Inc is a holding company that engages in the provision of technology solutions. It operates through the following segments: Healthcare Solutions, Commercial Solutions, and Corporate. The Healthcare Solutions segment provides healthcare information technology products and services to the US healthcare market. The Commercial Solutions segment offers technology solutions and services to businesses in the United States. The Corporate segment comprises of the company’s operations and investments.
– Sophia Genetics SA ($NASDAQ:SOPH)
Sophia Genetics is a data-driven, artificial intelligence-enabled molecular diagnostics company. The company has a market cap of $124.46M and a ROE of -23.95%. Sophia Genetics’ products and services are used by hospitals and laboratories around the world to improve patient care by providing more accurate and timely diagnosis of genetic diseases.
Summary
HEALTH CATALYST recently reported its financial results for the second quarter of FY2023, showing total revenue increasing by 3.7% year-on-year to USD 73.2 million and net income decreasing by 2.5% to USD -32.6 million compared to the same period of the prior year. This caused the stock price to drop, leading investors to take a closer look at the company’s performance. Although revenue showed growth, the sizable decrease in net income raised red flags and could be a sign of a potential problem in the company’s operations. Investors should pay attention to any changes in HEALTH CATALYST’s financials and monitor the stock price to get a better idea of the direction the company is heading in.
Related Posts
Recent Posts
